BioSight
Companies
Larimar Therapeutics, Inc. logo

LRMR

NASDAQBALA CYNWYD, PA
Larimar Therapeutics, Inc.

Larimar Therapeutics develops drug candidates using a therapeutic modality targeting Friedreich's ataxia, a neurological disease. The company's lead candidate is nomlabofusp (CTI-1601), which is currently in clinical-stage development, with an ongoing open-label trial and planned Phase 3 studies. Larimar faces typical biotech risks including the need to demonstrate safety and efficacy to the FDA and other regulators, as well as challenges in patient recruitment and potential competitive pressures.

Price history not yet available for LRMR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar